Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Tiotropium bromide + Olodaterol; Device: Sp(t)iolto® Respimat®

Study type: Observational

Funder types: Industry

Identifiers

NCT04926233

1237-0091

Details and patient eligibility

About

The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.

Enrollment: 1,371,146 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• parent cohort

  -- COPD diagnosis

• child cohort

  -- any initiation of first maintenance therapy after July 1, 2015

• grandchild cohort -- any initiation of second maintenance therapy after August 2, 2015

Exclusion criteria

• parent cohort

• age <40 on index date
• any COPD diagnosis in baseline
• any use of long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), or inhaled corticosteroid (ICS) in baseline
• <365 days of continuous medical and pharmacy coverage

Trial design

1,371,146 participants in 2 patient groups

COPD patients from US IBM Marketscan database

Treatment:

Device: Sp(t)iolto® Respimat®

Drug: Tiotropium bromide + Olodaterol

COPD patients from UK CPRD GOLD database

Treatment:

Device: Sp(t)iolto® Respimat®

Drug: Tiotropium bromide + Olodaterol